- The FDA has approved the expanded use of Roche Holding AG’s (OTC:RHHBY) Xofluza (baloxavir marboxil).
- The medicine has been approved to treat acute uncomplicated influenza in otherwise healthy children aged 5-12 years who have shown symptoms for no more than 48 hours.
- This marks the first single-dose oral influenza medicine approved in the US for children in this age group.
- The FDA also approved Xofluza to prevent influenza in children aged five years to less than 12 years following contact with an infected person.
- Roche said Xofluza is already FDA-approved to treat influenza in people aged 12 and above.
- Price Action: RHHBY shares are up 1.71% at $41.74 during the market session on the last check Friday.
Keybanc Maintains Overweight on Advanced Micro Devices, Raises Price Target to $95
Keybanc analyst John Vinh maintains Advanced Micro Devices (NASDAQ:AMD) with a Overweight and raises the price target from $80 to $95.
